{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pervasive+Developmental+Disorder+Not+Otherwise+Specified",
    "query": {
      "condition": "Pervasive Developmental Disorder Not Otherwise Specified"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 16,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pervasive+Developmental+Disorder+Not+Otherwise+Specified&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:45:53.183Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01592786",
      "title": "An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder (ASD)",
        "Autism",
        "Autistic Disorder",
        "Asperger's Disorder",
        "Asperger's",
        "Pediatric Autism",
        "Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)"
      ],
      "interventions": [
        {
          "name": "Memantine Hydrochloride (HCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 906,
      "start_date": "2012-06",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2014-08-07",
      "last_synced_at": "2026-05-22T08:45:53.183Z",
      "location_count": 72,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01592786"
    },
    {
      "nct_id": "NCT01563003",
      "title": "Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Autism",
        "Asperger's Syndrome",
        "Pervasive Developmental Disorder Not Otherwise Specified",
        "Generalized Anxiety Disorder",
        "Social Phobia",
        "Separation Anxiety Disorder",
        "Obsessive-compulsive Disorder"
      ],
      "interventions": [
        {
          "name": "Cognitive Behavioral Therapy",
          "type": "OTHER"
        },
        {
          "name": "Treatment as usual",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "11 Years to 16 Years"
      },
      "enrollment_count": 31,
      "start_date": "2011-06",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2015-04-17",
      "last_synced_at": "2026-05-22T08:45:53.183Z",
      "location_count": 1,
      "location_summary": "St. Petersburg, Florida",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01563003"
    },
    {
      "nct_id": "NCT01592747",
      "title": "Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autistic Disorder",
        "Autism",
        "Asperger's Disorder",
        "Asperger Syndrome",
        "Autism Spectrum Disorders",
        "Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)"
      ],
      "interventions": [
        {
          "name": "Memantine Hydrochloride (HCl)",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 479,
      "start_date": "2012-09",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2019-04-24",
      "last_synced_at": "2026-05-22T08:45:53.183Z",
      "location_count": 64,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01592747"
    },
    {
      "nct_id": "NCT02028247",
      "title": "Psychotherapy for Anxiety in Children With Autism Spectrum Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Autism Spectrum Disorders",
        "Autism",
        "Asperger's Syndrome",
        "Pervasive Developmental Disability - Not Otherwise Specified",
        "Obsessive-compulsive Disorder",
        "Social Phobia",
        "Generalized Anxiety Disorder",
        "Specific Phobia",
        "Separation Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Personalized Cognitive-behavioral therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard Practice Cognitive-behavioral therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Treatment as Usual",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "13 Years",
        "sex": "ALL",
        "summary": "7 Years to 13 Years"
      },
      "enrollment_count": 214,
      "start_date": "2014-04",
      "completion_date": "2018-10",
      "has_results": true,
      "last_update_posted_date": "2021-11-15",
      "last_synced_at": "2026-05-22T08:45:53.183Z",
      "location_count": 1,
      "location_summary": "St. Petersburg, Florida",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02028247"
    },
    {
      "nct_id": "NCT01919970",
      "title": "Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Autism",
        "Asperger's Syndrome",
        "Pervasive Developmental Disorder Not Otherwise Specified",
        "Generalized Anxiety Disorder",
        "Social Phobia",
        "Separation Anxiety Disorder",
        "Obsessive-compulsive Disorder",
        "Specific Phobia"
      ],
      "interventions": [
        {
          "name": "Cognitive Behavioral Therapy",
          "type": "OTHER"
        },
        {
          "name": "Treatment as usual",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 32,
      "start_date": "2013-08",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2019-06-14",
      "last_synced_at": "2026-05-22T08:45:53.183Z",
      "location_count": 1,
      "location_summary": "St. Petersburg, Florida",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01919970"
    },
    {
      "nct_id": "NCT00773812",
      "title": "Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Autistic Disorder",
        "Pervasive Developmental Disorder"
      ],
      "interventions": [
        {
          "name": "mecamylamine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "4 Years to 12 Years"
      },
      "enrollment_count": 20,
      "start_date": "2007-07",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-05-22T08:45:53.183Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00773812"
    },
    {
      "nct_id": "NCT00709202",
      "title": "Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Schizophreniform Disorder",
        "Bipolar I Disorder",
        "Bipolar II",
        "Bipolar NOS(Not Otherwise Specified)",
        "Psychotic Disorder Not Otherwise Specified",
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Betahistine",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nathan Kline Institute for Psychiatric Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 48,
      "start_date": "2008-07",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2019-01-25",
      "last_synced_at": "2026-05-22T08:45:53.183Z",
      "location_count": 1,
      "location_summary": "Orangeburg, New York",
      "locations": [
        {
          "city": "Orangeburg",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00709202"
    },
    {
      "nct_id": "NCT01592773",
      "title": "Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder (ASD)",
        "Autism",
        "Autistic Disorder",
        "Asperger's Disorder",
        "Asperger's",
        "Pediatric Autism",
        "Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)"
      ],
      "interventions": [
        {
          "name": "Memantine Hydrochloride (HCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 747,
      "start_date": "2012-10",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2015-02-16",
      "last_synced_at": "2026-05-22T08:45:53.183Z",
      "location_count": 68,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01592773"
    },
    {
      "nct_id": "NCT01160783",
      "title": "Genetic Contributions to Autism Spectrum Disorders",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Autism Spectrum Disorder",
        "Autism",
        "Asperger's Syndrome",
        "Pervasive Developmental Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Months and older"
      },
      "enrollment_count": 240,
      "start_date": "2007-04",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-05-22T08:45:53.183Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01160783"
    },
    {
      "nct_id": "NCT01269710",
      "title": "Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Schizophreniform Disorder",
        "Psychotic Disorder, Not Otherwise Specified",
        "Prodromal Schizophrenia",
        "Mood Disorder",
        "Bipolar Disorder",
        "Major Depressive Disorder",
        "Depressive Disorder, Not Otherwise Specified",
        "Mood Disorder, Not Otherwise Specified",
        "Autism Spectrum Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "3 Years to 19 Years"
      },
      "enrollment_count": 4,
      "start_date": "2009-10",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2013-02-22",
      "last_synced_at": "2026-05-22T08:45:53.183Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01269710"
    }
  ]
}